Keyphrases
3-phase
10%
Acceleration Time
10%
All Ages
10%
Alvimopan
100%
Before Surgery
10%
Bowel Resection
100%
Cox Proportional Hazards Model
10%
Discharge Order
20%
Further Analysis
10%
GI Function
10%
Hazard Ratio
10%
Hospital Discharge
20%
Hospital Readmission
20%
Hysterectomy
10%
In(III)
10%
Morbidity Rate
10%
Mu-opioid Receptor Antagonist
10%
Phase II Study
100%
Phase II Trial
20%
Placebo
30%
Pooled Analysis
100%
Postoperative Ileus
100%
Postoperative Morbidity
20%
Prolonged Hospital Stay
20%
Readmission
10%
Recovery Time
10%
Subset Analysis
10%
Time to Discharge
10%
Time-to-event Endpoint
10%
Tolerability
10%
Treatment Effect
10%
Twice Daily
10%
Pharmacology, Toxicology and Pharmaceutical Science
Alvimopan
100%
Morbidity
10%
Mu Opiate Receptor Antagonist
10%
Placebo
30%
Postoperative Ileus
100%
Tolerability
10%